In a rabbit model, we have previously reported evidence for a pathogenic role of streptococcal IgG Fc-binding proteins (IgGFcBP) in poststreptococcal glomerulonephritis (PSGN). These proteins, of the M protein family, were shown to trigger anti-IgG production and enhance renal deposition of IgG and/or immune complexes (ICs), with resulting activation of complement and cytokine cascades. In the present study, type M12/emm12, group A streptococci (GAS) were found often to bind artificial ICs, viz. peroxidase-anti-peroxidase rabbit IgG (PAP) or tetanus toxoidanti-tetanus human IgG (TAT), rather than monomeric IgG. Animals injected with each of four IC binding clinical isolates (from patients with scarlet fever or PSGN) showed pronounced inflammatory and degenerative glomerular changes, morphologically similar to human PSGN, with membrane thickening and IgG and complement C3 deposition, as well as secretion of IL-6 and TNF-a by mesangial and endothelial cells. In contrast, non-binding strains (two from asymptomatic carriers and one from a PSGN case) failed to trigger any renal changes. Only the IC binding strains induced elevated titres of anti-IgG. Though the streptococcal binding component(s) has not been demonstrated, the selective binding of ICs by type M12/emm12 strains appears important for the well-known, marked nephritogenic potential of this GAS type.
INTRODUCTION
Streptococcus pyogenes, or group A streptococcus (GAS), is a leading cause of both superficial and invasive disease, but also gives rise to severe non-suppurative complications, such as acute rheumatic fever (ARF) and poststreptococcal glomerulonephritis (PSGN), causing significant morbidity and mortality in low-income parts of the world (Carapetis et al., 2005) . Based on the hypervariability of the surface M protein, or corresponding emm gene, GAS are currently subdivided into more than 200 serotypes/genotypes (Bessen et al., 2008) . It is recognized, however, that both ARF and PSGN are preferentially caused by a limited number of non-identical types, in the case of PSGN predominantly M-types 1, 2, 4, 12, 25, 49, 56, 57, and 60 (Cunningham, 2000; Martin, 1997; Stollerman, 1971) .
The M protein is critical for the virulence of GAS, its antiphagocytic action being related to a capacity to bind fibrinogen or the complement inhibitor C4BP (Carlsson et al., 2005; Fischetti, 1989; Waldemarsson et al., 2009 ).
Many GAS strains express one or two additional M-like proteins, and members of the M protein family may also interact with several other host proteins, such as IgG, IgA, HSA, complement factor H, fibronectin, kininogen and plasminogen, contributing to i.a. bacterial disguise, epithelial adhesion, vascular leakage and platelet-neutrophil complex formation (Oehmcke et al., 2010) . With regard to IgG, the Fc part of the molecule is targeted, enabling blocking of the interaction between C1q and immune complexes (ICs) (Schalén et al., 1985a) , and also generation of soluble, non-immune M protein-IgG complexes (Berge et al., 1997) .
While pathogenic events leading to PSGN are not known in detail, the time lag of some weeks between the acute disease and typical renal deposition of IgG and complement factor C3 may suggest an important role of circulating IC, or local complex formation (Eison et al., 2011; Kambham, 2012; Silva, 1998) . The occurrence of circulating anti-IgG in a proportion of patients with PSGN has also been reported (McIntosh et al., 1979; Sesso et al., 1986) . Though animal models mimicking the disease are scarce, our previous studies showed that immunization of rabbit with whole GAS tends to trigger formation of anti-IgG as well as renal deposition of IgG and C3, and histological changes (Burova et al., 1985 (Burova et al., , 1992 . In our hands, these biological effects required the use of IgG Fc-binding, rather than non-binding, GAS strains (Burova et al., 1998) . Furthermore, confirming our findings with wild strains, two isogenic mutants of a type M22 strain (AL168) retaining at least one of two genes for IgG Fcbinding proteins (IgGFcBPs) were still able to induce experimental glomerulonephritis, whereas a mutant strain lacking both genes was not (Burova et al., 2003) . These combined results, using an artificial animal model, thus indicated a possible pathogenic role of the streptococcal IgGFcBPs in PSGN.
More recently, two IgGFcBPs (Emm22 and Mrp22), purified from the above-mentioned type M22 strain were found to induce glomerular changes comparable to those caused by whole bacteria; this, to our knowledge, represented the first report of an isolated streptococcal component causing PSGN-like experimental lesions. Also notably, the induction by whole streptococci (type M1) of glomerular changes was inhibited by the intravenous administration of purified human or rabbit IgG Fc, but not Fab, fragment (Burova et al., 2012) , which provided more direct support for the involvement of the IgGFcBPs in eliciting poststreptococcal renal experimental damage. Based on these and previous data, we proposed that both streptococcal IgGFcBP and anti-IgG antibody, induced by this bacterial factor, facilitated renal accumulation of IgGcontaining complexes, which in turn acted to trigger local complement and proinflammatory cascades.
Among nephritogenic streptococci, M12/emm12 strains are globally prevalent. This type unusually binds IgG3 but not other subclasses of IgG (Retnoningrum et al., 1993) . On the other hand, many type M12 isolates were also found to bind aggregated, rather than native, human IgG (Schalén et al., 1986; Schalén et al., 1985b) . In the present work, the nephritogenic potential of type M12/emm12 isolates from different sources was examined in our rabbit model, with special reference to a possible role of the capacity to interact with complex bound IgG. 
METHODS
Bacterial strains. Twenty-one GAS type M12 strains isolated from patients with PSGN, and the reference strain M12/1800, were obtained courtesy of Dr J. Sramek, WHO Streptococcal Reference Laboratory, Prague. In addition, three randomly chosen strains isolated from patients with scarlet fever (emm12/94, emm12/113, emm12/118) and two strains from asymptomatic throat carriers (emm12/139, emm12/ 171) were obtained from the Paediatric Infectious Hospital, and from day care nurseries, St Petersburg; the strains were epidemiologically unrelated. For emm gene sequencing, DNA primers listed in Table 1 were used.
Bacterial binding of ICs. Peroxidase-anti-peroxidase IgG (PAP) complexes were prepared as follows. Horseradish peroxidase (HRP; type 1, Sigma) 1 mg ml 21 was dissolved in 25 mM Tris/HCl, 0.15 M NaCl, pH 7.4 (TBS) yielding 22.7 mM (based on 44 kDa for Tris). Rabbit anti-HRP (Dako A/S) at 26.7 mM (based on 150 kDa for IgG) was mixed with HRP at a 2 : 3 Ab : Ag molar ratio, vortexed briefly and incubated overnight at 4 uC for complex formation. The bacterial binding of PAP was tested qualitatively by colony dot-blot as follows. A nitrocellulose membrane was placed on the surface of an agar plate with streptococcal colonies (grown for 18-20 h at 37 uC) for 20 min at room temperature. The membrane was transferred to a filter paper moistened with fixing solution (200 mg SDS, 8 ml 5M NaOH, 1 ml b-mercaptoethanol in 200 ml H 2 O). After 30 min, the membrane was washed extensively in PBS, incubated for 10 min in 0.2 mM TBS, pH 8.0, with 1 % BSA (TBS-BSA) and 25 mg l 21 DNase. After washes in 0.2 mM TBS with 0.1 % Tween-20 (TBS-T), the membrane was incubated for 1 h with TBS-BSA and then washed in 0.2 mM TBS-T and 0.2 mM TBS, respectively. Incubation with PAP was performed at pH 5.5, found optimal for the binding. After 1.5-2 h at room temperature, the membrane was washed with TBS-T and finally with TBS. The substrate used was chloronaphthol.
Tetanus-anti-tetanus (TAT) complexes were constructed from tetanus toxoid (SBL Vaccine) and human anti-tetanus IgG (Tetagam P, Behringwerke); the toxoid was radiolabelled with 125 I using Iodo-beads (Pierce Chemicals) according to the manufacturers' instructions; optimal conditions for the radiobinding assay proved to be an Ab : Ag molar ratio 1 : 1, and use of TBS buffer at pH 6.0. Binding of radiolabelled, monomeric commercial IgG, in TBS at pH 8.0, was tested as described (Burova et al., 1989) .
Animal experimentation. Animal experiments were carried out at the Department of Molecular Microbiology, Institute of Experimental Medicine according to Animal Welfare Assurance #A5243-01. Female Chinchilla rabbits weighing 2.5-3.0 kg, obtained from the animal nursery 'Rappolovo' (St-Petersburg), were used. Selected GAS strains were tested in a previously described rabbit model (Burova et al., 2003) ; in brief, strains were grown aerobically in Todd-Hewitt broth (THB) overnight, heat-killed, treated with 1 M KSCN, and washed six times in PBS in order to remove any bound IgG (Burova et al., 1989) . Rabbits were injected with streptococci in 1 ml PBS (10 9 c.f.u. ml 21 ) three times weekly for 6 weeks. One week later, the animals were euthanized and kidneys were taken for investigations.
Anti-IgG determination. Anti-human IgG in rabbit sera was titrated by indirect haemagglutination in microtitre plates using Ripleycoated human red blood cells (Burova et al., 1985) .
Immunomorphological examination of renal tissue. Two out of three rabbits injected with each strain from patients with PSGN were examined immunohistochemically and by transmission electron microscopy (TEM); those rabbits injected with scarlet fever or carriage-associated strains were also studied morphometrically.
Tissue deposition of IgG was demonstrated by goat anti-rabbit IgG antibody followed by HRP-labelled rabbit anti-goat antibody (Southern Biotechnology Associates). Complement component C3 was detected by use of rabbit anti-human C3 (Dako), cross-reacting S. pyogenes type M12/emm12 in glomerulonephritis with rabbit C3, followed by HRP-labelled goat anti-rabbit IgG (Sigma). TNF-a and IL-6 were detected by goat anti-rabbit TNF-a (AMS Biotechnology) and anti-human IL-6 antibody (Biosource International), respectively, followed by HRP-labelled rabbit anti-goat antibody.
Initial morphological examination of tissue samples after haematoxylin and eosin staining was performed at low and middle magnification (6100-600) with the aim of evaluating the extent of tissue changes in a given field. Following immunostaining the tissue was investigated, at higher magnification (6900-1100), for IgG and C3 deposition or cytokine expression. Subcellular changes were examined by TEM. The details of these procedures were described previously (Burova et al., 1998) . Briefly, for TEM, tissue samples were incubated with 2.5 % glutaraldehyde solution in 0.1 M cacodylate buffer, pH 7.4, at 4 uC for 3 h. Following washes in the same buffer for 24 h the blocks were fixed with 1 % OsO 4 in cacodylate buffer, dehydrated in alcohol of increasing concentration and propylene oxide, and embedded in araldite. The material was visualized using a JEM 100B microscope operating at 75 kV.
Renal changes were morphometrically evaluated as follows. In the cortex, 10 fields of view at a 6700 magnification were randomly selected and the average numbers of normal and altered glomeruli were calculated separately. To measure the areas of damaged proximal tubules in the cortex or distal medullary tubules, a standard morphometric net (a large square consisting of 256 small squares) was placed on the tissue sample. The proportion of small squares with destructive-degenerative changes within one field of view was used to score the degree of alteration. White blood-cell infiltration was measured by a similar approach. The data were statistically processed as previously described (Collan, 1984) .
RESULTS

Binding of artificial ICs by streptococci
Streptococcal interaction with the PAP and TAT complexes was evaluated by colony dot-blot and radiobinding, respectively. Controls of Ab or Ag alone were invariably negative. Among 21 M12 strains isolated from cases of PSGN, 19 demonstrated quite distinct binding of PAP, whereas two failed to bind (Fig. 1) . Most of these PSGN isolates (20 out of 21) also showed strong binding of TAT (30-40 %), and only one strain (M12/305) was negative for binding of both complexes. Finally, out of three throat isolates from patients with scarlet fever and two strains from symptom-free carriers, each of the former, but none of those from carriers, bound the two complexes studied. All tested isolates bound only low amounts of native human IgG (Table 2) .
Sequencing the emm gene
Studying two of the scarlet fever and the two carrier isolates as well as two isolates from patients with PSGN, the entire DNA sequence of the respective emm gene (GenBank accession numbers: emm12/94-KC588908, emm12/118-KC588909, emm12/139-KC588910, emm12/171-KC588911, emm12/257-KC588912, emm12/305-KC588913) was identical, and similar to the six emm12 sequences previously 
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deposited in the GenBank database. Thus, no sequence variation among our tested strains was found.
Circulating anti-IgG
At the end of immunization (1 week following the last injection), all six rabbits receiving M12/1800 or PSGN strain M12/257 exhibited high levels of circulating anti-IgG (1 : 80-1 : 160); however, none of the three receiving strain M12/305 developed any detectable anti-IgG (Table 3) .
Comparing the induction of anti-IgG by scarlet fever and carrier isolates, none out of six animals injected with a carrier strain exhibited anti-IgG, whereas all 12 rabbits receiving either of the three scarlet fever strains or M12/ 1800 showed titres between 1 : 40 and 1 : 160 (Table 4) .
Renal findings
First, renal tissue samples from six rabbits injected with either M12/1800 or the human PSGN-associated strains M12/257 or M12/305 were morphologically studied. No deposits or signs of tissue inflammation were found in those receiving M12/305. In contrast, in those receiving M12/1800 or M12/257, deposition of IgG and C3, mainly on the glomerular membrane, was found (Figs 2 and 3); this was accompanied by presence of TNF-a and IL-6 in mesangial and endothelial cells and in interstitial tissue, as well as glomerular changes within basement membrane and intracapillary structures. Local thickening of the basement membrane, destroyed epithelium, intense proliferation of mesangial cells, hypertrophy, vacuolization and disintegration of podocytes and their processes were observed ( Fig. 3 and Table 3 ). These morphological changes could be classified as membranous-proliferative glomerulonephritis, as previously reported (Burova et al., 1998 (Burova et al., , 2003 (Burova et al., , 2012 , and compatible with the picture seen in human PSGN (Kambham, 2012) .
Comparing scarlet fever (emm12/94, emm12/113, emm12/ 118) and carrier (emm12/139, emm12/171) isolates, none of the latter induced any marked renal pathology. In contrast, all rabbits injected with the scarlet fever isolates showed glomerular changes characteristic for membranous-proliferative glomerulonephritis (Fig. 4) including IgG and C3 deposits and presence of TNF-a and IL-6 as above. The degree of changes was also assessed morphometrically: As shown in Table 4 , number of glomeruli with degenerative changes was much higher in those animals injected with scarlet fever, as compared to carrier, strains. Also, proximal tubules with pathological changes and/or cell inflammatory infiltrates were abundant in rabbits injected with scarlet fever isolates, but absent in those receiving carrier strains. Analogously, the number of distal tubules with changes and cell inflammatory infiltration was higher for scarlet fever isolates than for carrier strains. Thus, as opposed to the scarlet fever strains, the carrier strains evoked only minor tissue alterations considered to be reversible. It should be noted, however, that scarlet fever isolate emm12/118 caused less pronounced glomerular pathology and no distal tubular changes.
DISCUSSION
Non-immune interaction with mammalian IgGFc has been demonstrated in a majority of GAS types and clinical isolates (Kronvall, 1973; Lindahl & Stenberg, 1990) , and shown to be mediated by surface proteins of the M family (Frithz et al., 1989; Heath & Cleary, 1989) . Interestingly, these IgGFcBPs of GAS have been found to segregate structurally and functionally (Raeder et al., 1991) , and in type M12/emm12, an important nephritogenic type, binding of human monomeric IgG seems restricted to IgG3 (Retnoningrum et al., 1993) . Nevertheless, a marked affinity for aggregated, polyclonal IgG was previously revealed for GAS type M12 strains (Schalén et al., 1985b (Schalén et al., , 1986 . Here, we report that human or rabbit in vitro generated ICs also bind to type M12/emm12 streptococci. The biological relevance of this, so far uncharacterized, interaction remains speculative at this point.
As long assumed, the IgGFcBPs of GAS may potentially affect host defences and account for antiphagocytic and other virulence mechanisms (Berge et al., 1997; Nordenfelt et al., 2012) . As mentioned, a tentative role of these IgGFcBPs in triggering glomerulonephritis in the rabbit has been shown by our group. According to a scenario suggested, circulating anti-IgG, induced by streptococcal IgGFcBP, will act to generate renal deposition of IgGcontaining complexes, possibly also containing IgGFcBP molecules. By interplay with mesothelial and other cells such aggregates may in turn trigger complement and proinflammatory cascades leading to glomerular injury, with deposits of factor C3 as well as cytokines TNF-a and IL-6 in mesangial and endothelial cells, as observed. These experimental results were obtained earlier with both conventional GAS strains of different M-types and, more recently, by isogenic mutants of type M22, retaining one of *For each strain, three rabbits were injected and anti-IgG titres were determined, but only two were examined morphometrically.
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Journal of Medical Microbiology 62 two IgGFcBPs, whereas a double mutant did not cause any renal pathology. More remarkably, each of the two IgGFcBPs, isolated from the same M22 strain, were found to trigger renal damage, apparently in a similar way, and isolated IgG Fc, but not the Fab fragment, was found to abrogate the triggering of damage by whole streptococci (Burova et al., 2003 (Burova et al., , 2012 . Our combined results thus provide strong evidence for the participation of streptococcal IgGFcBPs in causing experimental glomerulonephritis, with the prior stimulation of circulating anti-IgG production evidently a sine qua non precondition. The possible presence of circulating ICs preceding the appearance of anti-IgG was not evaluated, though we hypothesize that streptococcal IgGBPs might act unconventionally to more directly trigger anti-IgG production. Such a concept was supported by our recent finding that isolated streptococcal IgGFcBP, similar to whole bacteria, acted to stimulate anti-IgG in the rabbit (Burova et al., 2012) . Furthermore, as shown here and previously in our rabbit model, streptococcal strains negative for binding of IgG or ICs did not evoke any detectable antiIgG. Further approaches to address this issue, however, should be of interest.
In the present work, type M12/emm12 isolates from human PSGN or scarlet fever cases, and from symptom-free pharyngeal carriers, were tested in the same rabbit model. All three scarlet fever strains proved positive for the binding of ICs, whereas the two carrier strains did not; only the former induced renal PSGN-like changes. Moreover, as judged from detailed morphometric, electron microscopic and immuno-histopathological analysis, the renal damage induced by these clinical strains, as compared to previously examined strains of other types, binding monomeric IgG, was practically indistinguishable, indicating that similar pathogenic mechanisms might be involved. The findings also demonstrated an apparent association of circulating anti-IgG and renal involvement, as shown by comparing PSGN isolates M12/257 and M12/305 (Table 3) , or the carrier vs scarlet fever isolates (Table 4) . Our data thus suggest that a selective IC binding ability of type M12/emm12 GAS may be essential for the nephritogenic potential of this serotype, a common type causing PSGN in humans.
An unexpected clinical correlate to the capacity to bind IC among our recent emm12 strains was found, since all strains that bound IC were isolates from patients with scarlet fever, whereas non-binding strains were from asymptomatic streptococcal carriers. Furthermore, 20 out of 21 M12 isolates from patients with PSGN were positive S. pyogenes type M12/emm12 in glomerulonephritis for binding of either of two artificial ICs tested. With the hypothesis that the M12 protein was responsible for IC binding, we examined the emm genes of some of the binding and non-binding strains. However, DNA sequencing of the entire, respective emm genes, including the B or C repeat regions responsible for the binding of monomeric IgG (Stenberg et al., 1994) , did not show any differences between strains. This suggests that it is not M12, but possibly some other GAS protein that accounts for the binding of ICs. Alternatively, there might be a difference 
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between disease and carrier GAS isolates at the level of M12 protein expression. Obviously, further examination of various M12/emm12 isolates is needed for any conclusions regarding an association between the clinical origin of strains and IC binding properties to be made.
The pathogenesis of PSGN has long been a matter of discussion, involving various streptococcal components, such as streptokinase, plasmin receptor and cysteine proteinase, also called SpeB, as well as immunological cross-reactivity between streptococci and renal tissue (Eison et al., 2011; Oda et al., 2010) . Any role of extracellular products, such as SpeB or streptokinase, was excluded here by the use of heat-killed and extensively washed streptococci for injection. At present, there are few animal models of the disease, and, with the exception of IgGFcBPs, isolated streptococcal components have not been reported to induce natural or experimental PSGN. The possible linkage of streptococcal IC binding to glomerulonephritis might represent a biologically intriguing variant of the situation with nephritogenic GAS strains binding monomeric IgG, a concept requiring further analysis of the process leading to poststreptococcal renal damage.
